USP22 and breast cancer: Further characterization by IHC staining show that the levels of USP22, FoxM1 and integrin b1 protein expression by USP22i-S02 treatment, which consequently inhibited the breast cancer cell growth because the percentage of Ki-67+ proliferative cells was dramatically decreased.